The YouTube ID of RpE6BgK4k3I is invalid.
Very detailed presentation using Rituximab in the treatment for Multiple Sclerosis at Neurology Grand Rounds on 15th of July 2015. Rituximab is widely used off-label to treat difficult cases of multiple sclerosis, systemic lupus erythematosus, chronic inflammatory demyelinating polyneuropathy and autoimmune anemias.
Patents on the drug in expired in Europe in February 2013 and in the US in September 2016. By February 2017 several biosimilars had been approved in India and one biosimilar had received approval in Europe.